Why the study?
Apical hypertrophic cardiomyopathy is an HCM subtype with few available studies on its prognosis.
Does the apical hypertrophic cardiomyopathy (AHCM) phenotype reduce all-cause mortality, cardiovascular mortality, and sudden cardiac death compared to non-AHCM in patients with hypertrophic cardiomyopathy?
Does the apical hypertrophic cardiomyopathy (AHCM) phenotype reduce all-cause mortality, cardiovascular mortality, and sudden cardiac death compared to non-AHCM in patients with hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Apical hypertrophic cardiomyopathy is associated with a more favorable prognosis, including lower all-cause mortality and sudden cardiac death, compared to non-apical hypertrophic cardiomyopathy.
BACKGROUND: Apical hypertrophic cardiomyopathy (AHCM) is a subtype of HCM, and few studies on the prognosis in AHCM are available. AIMS: This study aimed to explore the clinical prognosis for AHCM and non-AHCM patients through clinical data based on propensity score matching (PSM) in a large cohort of Chinese HCM patients. METHODS: The cohort study included 2268 HCM patients, 226 AHCM and 2042 non-AHCM patients from 13 tertiary hospitals, who were treated between 1996 and 2021. Fifteen demographic and clinical variables of 226 AHCM patients and 2042 non-AHCM patients were matched using 1:2 PSM. A Cox proportional hazard regression model was constructed to assess the effect of AHCM on mortality. RESULTS: During a median follow-up of 5.1 (2.4-8.4) years, 353 (15.6%) of the 2268 HCM patients died, of whom 205 died due to cardiovascular mortality/cardiac transplantation and 94 experienced sudden cardiac death (SCD). In the matched cohort, the ACHM patients had lower rates of all-cause mortality (P = 0.003), cardiovascular mortality/cardiac transplantation (P = 0.03), and SCD (P = 0.02) than the non-AHCM patients. Furthermore, the Cox proportional hazard regression model showed that AHCM was an independent prognostic predictor of all-cause HCM mortality (P = 0.004) and a univariable prognostic predictor of cardiovascular mortality/cardiac transplantation (P = 0.03) and for SCD (P = 0.03). However, AHCM was not significant in multivariable Cox regression models in relation to cardiovascular mortality/cardiac transplantation and SCD. CONCLUSION: AHCM had a favorable prognosis both before and after matching, with lower all-cause mortality, cardiovascular mortality/cardiac transplantation, and SCD than non-AHCM.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: